Isofol Medical AB (publ), founded in 2008, is a biotech company that is developing a new drug candidate for the treatment of advanced colorectal cancer.
Colorectal cancer (CRC) is the third most common form of cancer worldwide and there is a very high need for more effective drugs to treat this disease.
Vision:
“Isofol will help extend life and improve the quality of life for cancer patients”
Arfolitixorin is being developed and commercialized through a global licensing agreement with Merck & Cie in Germany. The licensing agreement also grants Isofol access to the unique patented manufacturing process for arfolitixorin.
2008
HeadquartersArvid Wallgrens Backe 20, 41346 Gothenburg – Sweden
161,515,440
IPOJan. 1, 2000
Stock exchange(s)Nasdaq Stockholm